Cytokinetics (NASDAQ:CYTK) Director Robert Landry Sells 1,000 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) Director Robert Landry sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $72.13, for a total transaction of $72,130.00. Following the completion of the sale, the director directly owned 8,184 shares in the company, valued at approximately $590,311.92. This trade represents a 10.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Stock Down 4.3%

Shares of Cytokinetics stock opened at $69.31 on Wednesday. Cytokinetics, Incorporated has a 52-week low of $47.22 and a 52-week high of $88.31. The company has a market capitalization of $8.62 billion, a P/E ratio of -9.60 and a beta of 0.36. The company has a 50 day moving average of $77.46 and a 200 day moving average of $72.80.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The firm had revenue of $28.62 million during the quarter, compared to analysts’ expectations of $17.59 million. The company’s revenue for the quarter was down 57.1% on a year-over-year basis. During the same period in the prior year, the company posted ($1.12) earnings per share. As a group, research analysts anticipate that Cytokinetics, Incorporated will post -5.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cytokinetics

Several large investors have recently modified their holdings of CYTK. Tidal Investments LLC lifted its holdings in shares of Cytokinetics by 24.7% during the second quarter. Tidal Investments LLC now owns 24,921 shares of the biopharmaceutical company’s stock worth $2,123,000 after purchasing an additional 4,938 shares during the period. WINTON GROUP Ltd acquired a new position in Cytokinetics in the 2nd quarter valued at $774,000. Integrated Wealth Concepts LLC acquired a new position in Cytokinetics in the 2nd quarter valued at $36,000. Squarepoint Ops LLC purchased a new position in Cytokinetics during the 2nd quarter worth $226,000. Finally, Nykredit A S purchased a new position in Cytokinetics during the 2nd quarter worth $444,000.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Royal Bank Of Canada cut their price target on Cytokinetics from $117.00 to $112.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cytokinetics in a research report on Friday. UBS Group upgraded Cytokinetics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $69.00 to $115.00 in a report on Monday, June 29th. Citigroup reissued a “market outperform” rating on shares of Cytokinetics in a research report on Friday, August 7th. Finally, Citizens Jmp boosted their target price on Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Eighteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $103.37.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Neutral Sentiment: CEO Robert I. Blum sold a combined 105,426 shares for approximately $7.34 million across September 14–15, reducing his direct holdings by roughly 22%. Because the sales were made under a pre-arranged Rule 10b5-1 plan, they may reflect scheduled portfolio diversification rather than a reaction to new company-specific information. SEC Form 4 filing
• Neutral Sentiment: Director Robert Landry separately sold 1,000 shares for $72,130 under a 10b5-1 plan. The relatively small transaction adds to the insider-selling activity but is not, by itself, a major fundamental signal. SEC director Form 4 filing
• Neutral Sentiment: Cytokinetics announced its ninth annual communications grant program, which will support cardiovascular-disease patient advocacy organizations. The initiative supports stakeholder engagement and awareness but is unlikely to materially affect near-term revenue or valuation. Grant program announcement
• Neutral Sentiment: Management presented at the Morgan Stanley Global Healthcare Conference, giving investors an opportunity to assess the company’s pipeline and commercialization plans. No clearly identified new major catalyst was provided in the supplied coverage. Morgan Stanley conference transcript
• Negative Sentiment: Commentary titled “Why Myqorzo Doesn’t Make Me a Buyer Yet” reflects investor caution about Myqorzo’s ability to establish a sufficiently attractive commercial opportunity. That skepticism can pressure CYTK until prescriptions, adoption, and revenue traction provide stronger evidence of the drug’s potential. Myqorzo investment commentary

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. The company applies expertise in muscle physiology and contractility to develop potential treatments for cardiovascular and neuromuscular diseases.

Its leading programs include aficamten, an investigational cardiac myosin inhibitor being developed for conditions involving abnormal heart-muscle contraction, including hypertrophic cardiomyopathy.